NBTX

Nanobiotix S.A. [NBTX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

NBTX Stock Summary

Top 10 Correlated ETFs

NBTX

Top 10 Correlated Stocks

NBTX

In the News

NBTX Financial details

Company Rating
-
Market Cap
275.43M
Income
-74.13M
Revenue
6.74M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
101
Optionable
No
Shortable
Yes
Earnings
22 Apr 2024
P/E
-4.27
Forward P/E
-
PEG
-0.75
P/S
68.93
P/B
-9
P/C
-
P/FCF
-8.85
Quick Ratio
1.3
Current Ratio
1.38
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.12
EPS next Y
-
EPS next Q
-
EPS this Y
21.48%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
1.53%
Revenue last 5Y
110.34%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-18.18%
SMA50
-30.77%
SMA100
-28.95%
Inst Own
-
Inst Trans
-
ROA
-95%
ROE
44740%
ROC
-2.14%
Gross Margin
79%
Oper. Margin
-978%
Profit Margin
-1194%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.75-11.0
52W High
+213.45%
52W Low
+3348%
RSI
62
Rel Volume
5.95
Avg Volume
20.84K
Volume
123.89K
Perf Week
61.88%
Perf Month
-2.21%
Perf Quarter
-17.63%
Perf Half Y
52.23%
-
-
-
-
Beta
1.252
-
-
Volatility
4.23%, 5.04%
Prev Close
9.36%
Price
34.48
Change
11.48%

Something similar

Top by Market Cap
NVD.DE
FXAIX
ABEA.DE
BRYN.DE
VTI
Top Correlated ETFs
VNAM
VNM
MORT
XFVT.L
SRET
Top Correlated Stocks
0QAV.L
AXGN
AEIN.DE
FHN-PE
GPK
Similar Market Cap
STS.L
EEX
BBH
DPG
TIG

Company Profile

Healthcare Biotechnology
  • Volume Average 20.84K
  • Market Capitalization 275.43M
  • Employee 101
  • CEO Mr. Laurent Levy Ph.D.
  • Headquarters Paris,FR
  • IPO Date 2020-12-11
  • Website https://www.nanobiotix.com

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.